Profiling circulating DNA and RNA to identify mechanisms of therapeutic resistance and response in metastatic castration-resistant prostate cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1098647

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Enzalutamide is a powerful hormone treatment that improves survival for men with advanced prostate cancer. Unfortunately, all prostate cancers eventually become resistant to enzalutamide and not all men initially respond to treatment. I will look for blood markers that predict which men benefit from enzalutamide treatment and try to understand how resistance to enzalutamide occurs. This may lead to more effective use of enzalutamide resulting in better outcomes in advanced prostate cancer.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $482,590.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Solid Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

androgen receptor | biomarkers | drug resistance | hormone-refractory prostate cancer | prostate cancer

Related Links